Stuart Schreiber has been searching for vulnerabilities in treatment-resistant cancer cells. Recently, he found one.
The Morris Loeb Professor of Chemistry & Chemical Biology and Howard Hughes Medical Institute Investigator published a new ground-breaking study, "Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway," in the July 2017 edition of Nature. The discovery "opens a potential new route to fight cancer in people who currently lack good treatment options because conventional ones don't work," according to a follow-up feature article in Chemical & Engineering News.
Arjun Raj, a researcher with the University of Pennsylvania, stressed the importance of Schreiber's research: "One of the most exciting findings is that treatment-resistant cancer cells have some convergent general principles that can be exploited therapeutically, instead of the case-by-case, whack-a-mole approach that is currently dominant [in fighting treatment-resistant cancer]. Identifying the GPX4 pathway raises many exciting therapeutic possibilities.”
Want to learn more about Stuart Schreiber?
Visit his Lab Website to learn more about his research to understand and treat infectious disease, neurodegenerative disease and cancer.